Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-21. Numbers and descriptions here follow the published literature rather than marketing material.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
== Diagnosis == GAMT deficiency can be suspected from clinical findings, although clinical findings are not suggestive of a specific diagnosis. The initial diagnosis is typically established via measurement of creatine, creatinine, and guanidinoacetate in plasma, cerebrospinal fluid, or dried blood spots. These measurements can distinguish among the different cerebral creatine deficiency disorders. In GAMT deficiency, laboratory testing of plasma will show decreased levels of creatine and increased levels of guanidinoacetate. A definitive diagnosis requires DNA sequencing of the GAMT gene and/or GAMT enzymatic activity assays. Brain magnetic resonance spectroscopy can also be used in diagnosis, and will show decreased levels of creatine in affected individuals. However, as this finding is seen in all three cerebral creatine deficiencies, further testing is needed to identify the specific defect. Treatment is most effective for GAMT deficiency with early diagnosis; however, the non-specific clinical findings mean a diagnosis is often delayed. Due to the efficacy of early treatment and the lengthy typical diagnostic journey, GAMT deficiency has been recommended for newborn screening by the United States Advisory Committee on Heritable Disorders in Newborns and Children. Newborn screening assays measure the amount of guanidinoacetate in a dried blood spot using tandem mass spectrometry. Abnormal results from a newborn screening test still need to be confirmed by testing in plasma or urine.
The term "national home" was intentionally ambiguous, having no legal value or precedent in international law, such that its meaning was unclear when compared to other terms such as "state". The term was intentionally used instead of "state" because of opposition to the Zionist program within the British Cabinet. According to historian Norman Rose, the chief architects of the declaration contemplated that a Jewish State would emerge in time while the Palestine Royal Commission concluded that the wording was "the outcome of a compromise between those Ministers who contemplated the ultimate establishment of a Jewish State and those who did not." Interpretation of the wording has been sought in the correspondence leading to the final version of the declaration. An official report to the War Cabinet sent by Sykes on 22 September said that the Zionists did not want "to set up a Jewish Republic or any other form of state in Palestine or in any part of Palestine" but rather preferred some form of protectorate as provided in the Palestine Mandate. A month later, Curzon produced a memorandum circulated on 26 October 1917 where he addressed two questions, the first concerning the meaning of the phrase "a National Home for the Jewish race in Palestine"; he noted that there were different opinions ranging from a fully fledged state to a merely spiritual centre for the Jews. Sections of the British press assumed that a Jewish state was intended even before the Declaration was finalized.
To study the double-shell system, after synthesis of the core CdSe nanocrystals, a layer of ZnSe was coated prior to the ZnS outer shell, leading to an improvement in fluorescent efficiency by 70%. Furthermore, the two additional layers were found to improve resistance of the nanocrystals against photo-oxidation, which can contribute to degradation of the emission spectra. It is also standard for surface passivation techniques to be applied to these core/double-shell systems, as well. As mentioned above, oleic acid is one such organic capping ligand that is used to promote colloidal stability and control nanocrystal growth, and can even be used to initiate a second round of ligand exchange and surface functionalization. However, because of the detrimental effect organic ligands have on PL efficiency, further studies have been conducted to obtain all-inorganic quantum dots. In one such study, intensely luminescent all-inorganic nanocrystals (ILANs) were synthesized via a ligand exchange process which substituted metal salts for the oleic acid ligands, and were found to have comparable photoluminescent quantum yields to that of existing red- and green-emitting quantum dots.
Sources: en.wikipedia.org
== Medical uses == Suzetrigine is indicated for the treatment of moderate to severe acute pain in adults. It was primarily studied in people with postoperative pain, including due to abdominoplasty and bunionectomy. However, a small minority of patients received suzetrigine for non-surgical pain, including arthralgias, limb pain, and sprains and strains. Treatment of acute pain using suzetrigine has not been studied beyond 14 days of use. In clinical studies conducted through 2024, suzetrigine reduced pain typically from 7 to 4 on the standard numeric scale used to rate pain. The efficacy of suzetrigine was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, one following abdominoplasty and the other following bunionectomy. Both trials found that suzetrigine reduced pain more effectively than placebo. Suzetrigine was not superior to placebo for the treatment of lumbosacral radiculopathy. However, in clinical studies, no superiority over hydrocodone and paracetamol (acetaminophen) in terms of pain reduction was shown over 48 hours. Medical professionals have noted its efficacy may be inferior to high-dose opioid analgesics. There are no studies comparing suzetrigine with high-dose opioids. Suzetrigine exhibits CYP3A4-mediated drug interactions and there is limited long-term data regarding its use. Moreover, usage has not been studied in those younger than 18 or older than 80 years of age and its cost-effectiveness is disputed.
== Uses == Trap baits containing dimethyl trisulfide have been used to capture Calliphora loewi and other blowflies. Dimethyl trisulfide has been found to be an effective cyanide antidote in a rodent model for cyanide poisoning both against subcutaneous potassium cyanide and inhaled hydrogen cyanide, converting cyanide to much less toxic thiocyanate. It is suggested that dimethyl trisulfide can be used in a mass casualty cyanide exposure setting. In conjunction with these studies, the LD50 of dimethyl trisulfide in CD-1 mice was found to be 598.5 mg/kg, which may be compared to the LD50 of potassium cyanide of 8.0 mg/kg.
Karyolysis: the chromatin of the nucleus fades due to the loss of the DNA by degradation. Karyorrhexis: the shrunken nucleus fragments to complete dispersal. Pyknosis: the nucleus shrinks, and the chromatin condenses. Other typical cellular changes in necrosis include:
Sources: en.wikipedia.org
The esophagus (American English) or oesophagus (British English) ( ), also known as the gullet, is an organ in vertebrates through which food passes, aided by peristaltic contractions, from the pharynx to the stomach. The esophagus is a fibromuscular tube, about 25 cm (10 in) long in adult humans, that travels behind the trachea and heart, passes through the diaphragm, and empties into the uppermost region of the stomach. During swallowing, the epiglottis tilts backwards to prevent food from going down the larynx and lungs. The word esophagus is from Ancient Greek οἰσοφάγος (oisophágos), from οἴσω (oísō), future form of φέρω (phérō, "I carry") + ἔφαγον (éphagon, "I ate"). The wall of the esophagus from the lumen outwards consists of mucosa, submucosa (connective tissue), layers of muscle fibers between layers of fibrous tissue, and an outer layer of connective tissue. The mucosa is a stratified squamous epithelium of around three layers of squamous cells, which contrasts to the single layer of columnar cells of the stomach. The transition between these two types of epithelium is visible as a zig-zag line. Most of the muscle is smooth muscle although striated muscle predominates in its upper third. It has two muscular rings or sphincters in its wall, one at the top and one at the bottom. The lower sphincter helps to prevent reflux of acidic stomach content. The esophagus has a rich blood supply and venous drainage.
== Lipid metabolism disorders == Lipid metabolism disorders (including inborn errors of lipid metabolism) are illnesses that disrupt normal processes in breaking down or synthesizing fats (or fat-like substances). Lipid metabolism disorders are associated with an increase in the concentrations of plasma lipids in the blood such as LDL cholesterol, VLDL, and triglycerides, which most commonly leads to cardiovascular diseases. Often these disorders are hereditary. Gaucher's disease (types I, II, and III), Niemann–Pick disease, Tay–Sachs disease, and Fabry's disease are all disorders of lipid metabolism. Rarer disorders of lipid metabolism include sitosterolemia, Wolman's disease, Refsum's disease, and cerebrotendinous xanthomatosis.
An allegation spread in conservative media that SVB had donated over $73 million to the "BLM Movement & Related Causes," citing a database that had been created by a conservative organization to purportedly show "who funded the BLM riots". Analysis by Talking Points Memo found the database actually showed corporate donations to a variety of diversity programs that had no apparent relationship to the Black Lives Matter movement. The Associated Press also investigated claims that the collapse was caused by a "woke agenda" and found that there was no evidence to support the claims. Representative Nancy Mace of South Carolina criticized other members of Congress for politicizing the bank's failure and urged caution in making public comments that could affect the market.
A vibrator (such as a clitoral vibrator), dildo or other sex toy may be used. Other women stimulate the clitoris by use of a pillow or other inanimate object, by a jet of water from the faucet of a bathtub or shower, or by closing their legs and rocking.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.